AUTL News and Press, Autolus Therapeutics plc From 08/03/23

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Pivotal FELIX data at ASCO showed 76...

2023-08-02 14:04:22 ET Autolus Therapeutics ( NASDAQ: AUTL ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.22 (+52.2% Y/Y) and the consensus Revenue Estimate is $0.1M Over the last 3 months, ...

- Veronica Hersberger appointed as Senior Vice President, Medical Affairs - Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-...

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2023 financial results and operational highlights befo...

Long-term CAR T cell persistence is associated with durable responses in B-ALL Obe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years after infusion Single-cell analysis of persisting obe-cel CAR T cells sheds light on the ...

2023-07-05 17:32:16 ET Gainers: Cardlytics, Inc. ( NASDAQ: CDLX ) +9% . Autolus Therapeutics  ( AUTL ) +5% . Omeros ( OMER ) +4% . Arrival ( ARVL ) +3% . Nkarta ( NKTX ) +3% . Losers: IDEAYA Biosciences ( IDYA ...

2023-06-30 19:34:02 ET Summary Obe-cel and pipeline offer many catalysts in 2023. The CAR T-cell candidate offer a safer alternative to commercial rivals. Strong cash position should see the company through to obe-cel launch. Autolus Therapeutics ( AUTL ) is a mi...

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced a publication in Cancer Immunology Research 1 entitled: ‘Enhancing CAR T ce...

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Dr. Robert Iannone, Executive Vice President, Global Head of Research & Development o...

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A) Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months post-dosing at the highest dose tested Presence of CAR T cells in the lymph nodes of patien...